Prophylactic Lamivudine Administration Prevents Exacerbation of Liver Damage in HBe Antigen Positive Patients with Hepatocellular Carcinoma Undergoing Transhepatic Arterial Infusion Chemotherapy

Hiroaki Nagamatsu, Michio Sata(Kurume University), Takuji Torimura(Omuta hospital), Junichi Kurogi(Kurume University), Junji Akiyoshi(Kurume University), Satoru Matsugaki(Kurume University), Sakae Nagaoka(Kurume University), Ryukichi Kumashiro(Kurume University), Satoshi Itano(Kurume University Hospital), Nobuyoshi Tajiri(Kurume University), Sanki Yamasaki(Kurume University), Hironori Koga(Kurume University)
The American Journal of Gastroenterology
November 30, 2004
10.1111/j.1572-0241.2004.40069.x
Cited by 55

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504